Comparative Pharmacology
Head-to-head clinical analysis: TOLECTIN 600 versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOLECTIN 600 versus TOLECTIN DS.
TOLECTIN 600 vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
600 mg orally three times daily; maximum 1800 mg/day.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category C
Category C
NSAID
NSAID